Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126061 · ClinicalTrials.gov registry record · Phase 3
Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00126061 is a Phase 3 study that has completed, run by Solvay Pharmaceuticals.
The verdict
NCT00126061, a Phase 3 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in male patients.
Interventions
- DRUG Tedisamil sesquifumarate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-10 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126061
The ClinicalTrials.gov registry entry for NCT00126061 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tedisamil sesquifumarate is the first listed.
NCT00126061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00126061 about?
NCT00126061 is a clinical study titled "Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects". The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in male patients.
What is the current status of trial NCT00126061?
This trial is currently completed. It is a Phase 3 study. The study started on 2004-10. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00126061?
The interventions under investigation include: Tedisamil sesquifumarate (DRUG).
Who is sponsoring clinical trial NCT00126061?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.